CN101374840B - 7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用 - Google Patents

7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用 Download PDF

Info

Publication number
CN101374840B
CN101374840B CN2007800035988A CN200780003598A CN101374840B CN 101374840 B CN101374840 B CN 101374840B CN 2007800035988 A CN2007800035988 A CN 2007800035988A CN 200780003598 A CN200780003598 A CN 200780003598A CN 101374840 B CN101374840 B CN 101374840B
Authority
CN
China
Prior art keywords
alkyl
pyrido
pyrimidin
tolyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800035988A
Other languages
English (en)
Chinese (zh)
Other versions
CN101374840A (zh
Inventor
康拉德·霍诺尔德
简·保罗
卡尔·勒舍劳布
沃夫冈·舍费尔
斯蒂芬·沙伊布勒赫
托马斯·冯希施海特
艾伦·惠特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN101374840A publication Critical patent/CN101374840A/zh
Application granted granted Critical
Publication of CN101374840B publication Critical patent/CN101374840B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
CN2007800035988A 2006-01-31 2007-01-29 7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用 Expired - Fee Related CN101374840B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06001915 2006-01-31
EP06001915.5 2006-01-31
PCT/EP2007/000725 WO2007088014A1 (en) 2006-01-31 2007-01-29 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101374840A CN101374840A (zh) 2009-02-25
CN101374840B true CN101374840B (zh) 2011-09-28

Family

ID=36609592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800035988A Expired - Fee Related CN101374840B (zh) 2006-01-31 2007-01-29 7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用

Country Status (13)

Country Link
US (1) US8058283B2 (enExample)
EP (1) EP1981886B1 (enExample)
JP (1) JP2009525292A (enExample)
KR (1) KR20080083046A (enExample)
CN (1) CN101374840B (enExample)
AT (1) ATE439361T1 (enExample)
AU (1) AU2007211684A1 (enExample)
BR (1) BRPI0706781A2 (enExample)
CA (1) CA2636981A1 (enExample)
DE (1) DE602007001952D1 (enExample)
ES (1) ES2329419T3 (enExample)
IL (1) IL191748A0 (enExample)
WO (1) WO2007088014A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007001952D1 (de) 2006-01-31 2009-09-24 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
MX2014010176A (es) 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN105130986B (zh) 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
CN110016026B (zh) * 2018-01-08 2022-11-25 上海凌济生物科技有限公司 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途
KR102747104B1 (ko) * 2019-02-18 2024-12-27 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
KR102329720B1 (ko) * 2019-08-30 2021-11-23 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CN1138778C (zh) 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
HRP20010274A2 (en) 1998-10-23 2002-06-30 Hoffmann La Roche Bicyclic nitrogen heterocycles
HUP0203477A3 (en) 1999-10-21 2004-12-28 Hoffmann La Roche Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase, pharmaceutical compositions containing them and their preparations
ATE353329T1 (de) 1999-10-21 2007-02-15 Hoffmann La Roche Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
CA2420122A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
JP4141830B2 (ja) 2000-08-31 2008-08-27 エフ．ホフマン−ラ ロシュ アーゲー 細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
KR100864393B1 (ko) 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 피리미도 화합물
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
CA2542105C (en) * 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006012577A2 (en) * 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
DE602007001952D1 (de) 2006-01-31 2009-09-24 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren

Also Published As

Publication number Publication date
US8058283B2 (en) 2011-11-15
BRPI0706781A2 (pt) 2011-04-05
CA2636981A1 (en) 2007-08-09
EP1981886A1 (en) 2008-10-22
WO2007088014A1 (en) 2007-08-09
KR20080083046A (ko) 2008-09-12
EP1981886B1 (en) 2009-08-12
ATE439361T1 (de) 2009-08-15
JP2009525292A (ja) 2009-07-09
ES2329419T3 (es) 2009-11-25
AU2007211684A1 (en) 2007-08-09
US20090030020A1 (en) 2009-01-29
IL191748A0 (en) 2008-12-29
CN101374840A (zh) 2009-02-25
DE602007001952D1 (de) 2009-09-24

Similar Documents

Publication Publication Date Title
RU2326882C2 (ru) Пиримидиновые соединения, обладающие антипролиферативной активностью (ii)
CN114555585B (zh) Hpk1抑制剂及其用途
CN101374840B (zh) 7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用
ES2325440T3 (es) Compuestos de pirimidina.
KR101104666B1 (ko) 단백질 키나제 억제제로서의 헤테로아릴 유도체
SK3542002A3 (en) Pteridinones as kinase inhibitors
MXPA05006437A (es) Derivados de piridino[2,3-d]pirimidina como inhibidores selectivos de kdr y fgfr.
CA2589779A1 (en) Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
US6815439B2 (en) Substituted aza-oxindole derivatives
WO2016112846A1 (zh) 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
EP1919910B1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
Zhao et al. Discovery of thieno [3, 2-c] pyridin-4-amines as novel Bruton’s tyrosine kinase (BTK) inhibitors
CN101208339B (zh) 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
MX2008009462A (en) 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
AU2003274086C1 (en) Pyrimido compounds having antiproliferative activity (II)
HK1163679A1 (en) Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
HK1163679B (en) Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110928

Termination date: 20130129

CF01 Termination of patent right due to non-payment of annual fee